{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:24:49Z","timestamp":1788009889126,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s11864-024-01268-3","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:01:31Z","timestamp":1728619291000},"page":"1337-1344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"Parveen Kumar","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Sangwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"1268_CR1","unstructured":"American Cancer Society: Cancer Facts and Figures 2024. Available online Exit Disclaimer. 2024.\u00a0Accessed January 17, 2024."},{"key":"1268_CR2","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.21037\/tlcr-23-215","volume":"12","author":"A Addeo","year":"2023","unstructured":"Addeo A, Banna GL, Friedlaender A. Tarlatamab: a potential new option for recurrent small cell lung cancer. Transl Lung Cancer Res. 2023;12:1628\u201330. https:\/\/doi.org\/10.21037\/tlcr-23-215.","journal-title":"Transl Lung Cancer Res"},{"key":"1268_CR3","unstructured":"PDQ\u00ae Adult Treatment Editorial Board. PDQ Small Cell Lung Cancer Treatment. Bethesda, MD: National Cancer Institute. 2024. https:\/\/www.cancer.gov\/types\/lung\/hp\/small-cell-lung-treatment-pdq. Accessed 20 June 2024."},{"key":"1268_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","volume":"16","author":"CM Rudin","year":"2023","unstructured":"Rudin CM, Reck M, Johnson ML, Blackhall F, Hann CL, Yang JC, Bailis JM, Bebb G, Goldrick A, Umejiego J, Paz-Ares L. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16:66. https:\/\/doi.org\/10.1186\/s13045-023-01464-y.","journal-title":"J Hematol Oncol"},{"key":"1268_CR5","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO;2-Z","volume":"77","author":"WA Fry","year":"1996","unstructured":"Fry WA, Menck HR, Winchester DP. The national cancer data base report on lung cancer. Cancer. 1996;77:1947\u201355.","journal-title":"Cancer"},{"key":"1268_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AM Dingemans","year":"2021","unstructured":"Dingemans AM, Fr\u00fch M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, Lantuejoul S, Peters S, Reguart N, Rudin CM, De Ruysscher D. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:839\u201353. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.207.","journal-title":"Ann Oncol"},{"key":"1268_CR7","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","volume":"16","author":"F Blackhall","year":"2021","unstructured":"Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study. J Thorac Oncol. 2021;16:1547\u201358. https:\/\/doi.org\/10.1016\/j.jtho.2021.02.009.","journal-title":"J Thorac Oncol"},{"key":"1268_CR8","unstructured":"Serani S. FDA Grants Approval to Tarlatamab in Small Cell Lung Cancer. 2024.\u00a0https:\/\/www.targetedonc.com\/view\/fda-grants-approval-to-tarlatamab-in-small-cell-lung-cancer. Accessed 16 May 2024."},{"key":"1268_CR9","unstructured":"FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. News release. US FDA. May 16, 2024.\u00a0https:\/\/tinyurl.com\/bddwjpk2. Accessed 16 May 2024."},{"key":"1268_CR10","unstructured":"FDA grants priority review to Amgen\u2019s tarlatamab application for advanced small cell lung cancer. News release. Amgen. December 13, 2023. Accessed April 19, 2024."},{"key":"1268_CR11","unstructured":"Avanza T. FDA approves Imdelltra\u2122 (Tarlatamab-Dlle), the first and only T-cell engager therapy for the treatment of extensive-stage small cell lung cancer. 2024. Accessed May 16, 2024."},{"key":"1268_CR12","unstructured":"Richards R. Investing News Network Your trusted source for investing success. 2024. Accessed 20 Apr 2024."},{"key":"1268_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0745-2","volume":"12","author":"DH Owen","year":"2019","unstructured":"Owen DH, Giffin MJ, Bailis JM, Smit MA, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12:1\u20138. https:\/\/doi.org\/10.1186\/s13045-019-0745-2.","journal-title":"J Hematol Oncol"},{"key":"1268_CR14","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.21037\/tlcr-23-115","volume":"12","author":"D Tang","year":"2023","unstructured":"Tang D, Kang R. Tarlatamab: the promising immunotherapy on its way from the lab to the clinic. Transl Lung Cancer Res. 2023;12:1355. https:\/\/doi.org\/10.21037\/tlcr-23-115.","journal-title":"Transl Lung Cancer Res"},{"key":"1268_CR15","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3390\/ph16101461","volume":"16","author":"AA Khosla","year":"2023","unstructured":"Khosla AA, Jatwani K, Singh R, Reddy A, Jaiyesimi I, Desai A. Bispecific antibodies in lung cancer: a state-of-the-art review. Pharmaceuticals. 2023;16:1461. https:\/\/doi.org\/10.3390\/ph16101461.","journal-title":"Pharmaceuticals"},{"key":"1268_CR16","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.7150\/jca.75622","volume":"13","author":"B Oronsky","year":"2022","unstructured":"Oronsky B, Abrouk N, Caroen S, Lybeck M, Guo X, Wang X, Yu Z, Reid T. A 2022 update on extensive-stage small-cell lung cancer (SCLC). J Cancer. 2022;13:2945. https:\/\/doi.org\/10.7150\/jca.75622.","journal-title":"J Cancer"},{"key":"1268_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","volume":"14","author":"JK Sabari","year":"2017","unstructured":"Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14:549\u201361. https:\/\/doi.org\/10.1038\/nrclinonc.2017.71.","journal-title":"Nat Rev Clin Oncol"},{"key":"1268_CR18","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"issue":"16_Supplement","key":"1268_CR19","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1158\/1538-7445.AM2020-4558","volume":"80","author":"K Cooke","year":"2020","unstructured":"Cooke K, Estrada J, Zhan J, Werner J, Caenepeel S, Giffin M, Bailis JM, Coxon A, Hughes PE, Canon J. Antitumor activity of AMG757, a half-life extended (HLE) bispecific T-cell engager (BiTE\u00ae) immune therapy targeting DLL3, in human PDX and orthotopic mouse models of small cell lung cancer (SCLC). Cancer Res. 2020;80(16_Supplement):4558\u20134558. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-4558.","journal-title":"Cancer Res"},{"key":"1268_CR20","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","volume":"27","author":"MJ Giffin","year":"2021","unstructured":"Giffin MJ, Cooke K, Lobenhofer EK, Estrada J, Zhan J, Deegen P, Thomas M, Murawsky CM, Werner J, Liu S, Lee F. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27:1526\u201337. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2845.","journal-title":"Clin Cancer Res"},{"key":"1268_CR21","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1016\/j.jtho.2021.01.538","volume":"16","author":"K Cooke","year":"2021","unstructured":"Cooke K, Estrada J, Zhan J, Werner J, Bailis J, Hughes P, Shetty A, Canon J, Smit M. P15. 01 AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE\u00ae immune therapy) targeting DLL3, for the treatment of small cell lung cancer. J Thor Oncol. 2021;16:S343\u20134. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.538.","journal-title":"J Thor Oncol"},{"key":"1268_CR22","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1016\/j.jtho.2019.08.1131","volume":"14","author":"E Lobenhofer","year":"2019","unstructured":"Lobenhofer E, Werner J, Giffin M, Engwall M, Davies R, Homann O, Lafleur M, Moffat G. P1. 12-18 Nonclinical safety assessment of AMG 757, a DLL3 bispecific T cell engager, in the Cynomolgus Monkey. J Thor Oncol. 2019;14:S541. https:\/\/doi.org\/10.1016\/j.jtho.2019.08.1131.","journal-title":"J Thor Oncol"},{"key":"1268_CR23","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","volume":"41","author":"L Paz-Ares","year":"2023","unstructured":"Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study. J Clin Oncol. 2023;41:2893\u2013903. https:\/\/doi.org\/10.1200\/JCO.22.02823.","journal-title":"J Clin Oncol"},{"key":"1268_CR24","doi-asserted-by":"publisher","unstructured":"Ramalingam SS, Ahn MJ, Akamatsu H, Blackhall FH, Borghaei H, Hummel HD, Johnson ML, Reck M, Zhang Y, Jandial D, Cheng S. Phase 2 study of tarlatamab, a DLL3-targeting, half-life\u2013extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed\/refractory small cell lung cancer (SCLC). J Clin Oncol. 2022;40. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS8603","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8603"},{"key":"1268_CR25","doi-asserted-by":"publisher","first-page":"S1255","DOI":"10.1016\/j.annonc.2022.07.1643","volume":"33","author":"SM Gadgeel","year":"2022","unstructured":"Gadgeel SM, Al-Mondhiry J, Ahn MJ, Kim SW, Paz-Ares L, Prenen H, Boyer M, Alvarez JB, Solomon B, Huang S, Minocha M. 1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE\u00ae), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC). Ann Oncol. 2022;33:S1255. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1643.","journal-title":"Ann Oncol"},{"key":"1268_CR26","doi-asserted-by":"publisher","unstructured":"Paz-Ares LG, Felip E, Ahn MJ, Blackhall FH, Borghaei H, Cho BC, Johnson ML, Ramalingam SS, Reck M, Zhang A, Ju CH. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS8611","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8611"},{"key":"1268_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12943-024-02012-z","volume":"23","author":"PL Su","year":"2024","unstructured":"Su PL, Chakravarthy K, Furuya N, Brownstein J, Yu J, Long M, Carbone D, Li Z, He K. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy. Mol Cancer. 2024;23:97. https:\/\/doi.org\/10.1186\/s12943-024-02012-z.","journal-title":"Mol Cancer"},{"key":"1268_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"key":"1268_CR29","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1200\/JCO.23.00148","volume":"41","author":"S Tendler","year":"2023","unstructured":"Tendler S, Rudin CM. Tarlatamab: new star on the horizon for small-cell lung cancer? J Clin Oncol. 2023;41:2877\u201380.","journal-title":"J Clin Oncol"},{"key":"1268_CR30","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/cancers15051412","volume":"15","author":"DC Sim\u00e3o","year":"2023","unstructured":"Sim\u00e3o DC, Zarrabi KK, Mendes JL, Luz R, Garcia JA, Kelly WK, Barata PC. Bispecific T-cell engagers therapies in solid tumors: Focusing on prostate cancer. Cancers. 2023;15:1412. https:\/\/doi.org\/10.3390\/cancers15051412.","journal-title":"Cancers"},{"key":"1268_CR31","doi-asserted-by":"publisher","unstructured":"Cooke K, Estrada J, Zhan J, Werner J, Lee F, Shetty A, Smit MA, Salvati M, Bailis J. 627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE\u00ae) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer. 2020.\u00a0https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0627","DOI":"10.1136\/jitc-2020-SITC2020.0627"},{"key":"1268_CR32","doi-asserted-by":"publisher","unstructured":"Dingemans AM, Ahn MJ, Blackhall FH, Reck M, Hummel HD, Ramalingam SS, Johnson ML, Akamatsu H, Wolf J, Sands J, Owonikoko TK. DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)\u2014Efficacy and safety analyzed by presence of brain metastasis. 2024.\u00a0https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8015","DOI":"10.1200\/JCO.2024.42.16_suppl.8015"},{"key":"1268_CR33","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/genes15060701","volume":"15","author":"P Trillo Aliaga","year":"2024","unstructured":"Trillo Aliaga P, Del Signore E, Fuorivia V, Spitaleri G, Asnaghi R, Attili I, Corvaja C, Carnevale Schianca A, Passaro A, de Marinis F. The evolving scenario of ES-SCLC management: From biology to new cancer therapeutics. Genes. 2024;15:701. https:\/\/doi.org\/10.3390\/genes15060701.","journal-title":"Genes"},{"key":"1268_CR34","unstructured":"Study Comparing Tarlatamab and Durvalumab versus Durvalumab alone in first-line extensive-stage small-cell lung cancer (ES-SCLC) following Platinum, Etoposide and Durvalumab (DeLLphi-305). \nhttps:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06211036.\u00a0Accessed 29 Jun 2024."},{"key":"1268_CR35","unstructured":"Study Evaluating Tarlatamab After Chemoradiotherapy in limited-stage small-cell lung cancer (LS-SCLC) (DeLLphi-306). \nhttps:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06117774. Accessed 1 Jul 2024."},{"key":"1268_CR36","unstructured":"A Study of AMG 757 in participants with neuroendocrine prostate cancer (DeLLpro-300). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04702737, Accessed 23 June 2024."},{"key":"1268_CR37","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.3390\/jcm12247715","volume":"12","author":"S Stumpo","year":"2023","unstructured":"Stumpo S, Formelli MG, Persano I, Parlagreco E, Lauricella E, Rodriquenz MG, Guerrera LP, Zurlo IV, Campana D, Brizzi MP, Cives M, La Salvia A, Lamberti G. Extrapulmonary neuroendocrine carcinomas: current management and future perspectives. J Clin Med. 2023;12:7715. https:\/\/doi.org\/10.3390\/jcm12247715.","journal-title":"J Clin Med"},{"key":"1268_CR38","doi-asserted-by":"publisher","unstructured":"Aggarwal RR, Rottey S, Aparicio A, Greil R, Reimers MA, Sandhu SK, Zhang Y, Salvati M, Hashemi Sadraei N (2022) Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS19.","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS19"},{"key":"1268_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, Kochanek M, B\u00f6ll B, von Bergwelt-Baildon MS. Cytokine release syndrome. J Immunother. Cancer. 2018;6:1\u20134. https:\/\/doi.org\/10.1186\/s40425-018-0343-9.","journal-title":"Cancer"},{"key":"1268_CR40","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1126\/scitranslmed.aax8861","volume":"11","author":"J Li","year":"2019","unstructured":"Li J, Piskol R, Ybarra R, Chen YJ, Li J, Slaga D, Hristopoulos M, Clark R, Modrusan Z, Totpal K, Junttila MR, Junttila TT. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. 2019;11:861. https:\/\/doi.org\/10.1126\/scitranslmed.aax8861.","journal-title":"Sci Transl Med"},{"key":"1268_CR41","unstructured":"Tarlatamab (AMG 757) expanded access protocol for advanced small cell lung cancer. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06064500. Accessed 20 May 2024."}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01268-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-024-01268-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-024-01268-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T03:17:51Z","timestamp":1730863071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-024-01268-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1268"],"URL":"https:\/\/doi.org\/10.1007\/s11864-024-01268-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"assertion":[{"value":"25 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a review article. No ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}